{"id":740718,"date":"2023-03-16T08:36:32","date_gmt":"2023-03-16T12:36:32","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/shattuck-labs-presents-preclinical-data-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting\/"},"modified":"2023-03-16T08:36:32","modified_gmt":"2023-03-16T12:36:32","slug":"shattuck-labs-presents-preclinical-data-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/shattuck-labs-presents-preclinical-data-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting\/","title":{"rendered":"Shattuck Labs Presents Preclinical Data at the 2023 American Association for Cancer Research (AACR) Annual Meeting"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>\u2013 CD20-targeted\u00a0GADLEN demonstrated preclinical proof of concept of rapid B cell depletion in humanized mice and non-human primates, intended for clinical development in autoimmune disease <\/em><br \/>\n        <em>\u2013<\/em>\n      <\/p>\n<p>AUSTIN, TX and DURHAM, NC, March  16, 2023  (GLOBE NEWSWIRE) &#8212; Shattuck Labs, Inc. (Shattuck) (NASDAQ: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=f_twINMeaWB_xakaS1FBz9EWPHYKLbwQ4CRlyg197ZzBgNZYg7uIy_HZLrlj2XPRtUA7zn0fzZl-BVFh3UIVkQ==\" rel=\"nofollow noopener\" target=\"_blank\">STTK<\/a>), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease,\u00a0today announced preclinical data at the 2023 American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida, from the company\u2019s GADLEN platform.<\/p>\n<p>\u201cWe are pleased to share pre-clinical data demonstrating that the CD20-targeted GADLEN efficiently directs small numbers of human V\u03b39V\u03b42 T cells to serially kill greater than 99% of human B cells in a humanized mouse model,\u201d said\u00a0Taylor Schreiber, M.D., Ph.D., Chief Executive Officer of Shattuck. \u201cThese data led to the first study of a GADLEN compound in non-human primates, where once again treatment with a CD20-targeted GADLEN directed low frequencies of endogenous V\u03b39V\u03b42 T cells to eliminate CD20 positive B cells with a rapid kinetic. Importantly, the GADLEN compound was well tolerated in non-human primates up to the highest administered dose of 25 mg\/kg, without evidence of cytokine release syndrome or other toxicities, potentially providing differentiation from CD3-directed T cell engagers. These data underlie our enthusiasm to advance a GADLEN product candidate into the clinic designed for the treatment of antibody-mediated autoimmune diseases.\u201d<\/p>\n<p>Details of the presentations are as follows:<\/p>\n<p>\n        <strong>Abstract title:\u00a0Rapid Serial Killing of Target Cells by V\u03b39V<strong>\u03b4<\/strong>2 T Cells in Cynomolgus Macaques and Humanized Mice Treated with a CD20-Directed Heterodimeric Butyrophilin 2A1\/3A1 Fusion Protein<\/strong>\n      <\/p>\n<p>Shattuck to present preclinical data highlighting the potential of a CD20-targeted GADLEN to direct\u00a0V\u03b39V\u03b42 T cells to kill B cells <em>in vivo<\/em> in cynomolgus macaques and a humanized mouse model.<\/p>\n<p>Shattuck\u2019s bispecific GADLEN compound, which contains heterodimeric BTN2A1 and BTN3A1 extracellular domains fused via an inert Fc linker to an scFv domain targeting CD20 tumor-antigens, demonstrated an ability to rapidly deplete human and cynomolgus B cells in a dose-dependent manner.<\/p>\n<p>\n        <strong>Location:<\/strong>\u00a0Orange County Convention Center, Orlando, Florida<br \/><strong>Presenter: <\/strong>Dr.\u00a0Anne Lai, Ph.D., Associate Director R&amp;D, Shattuck Labs<br \/><strong>Session:\u00a0<\/strong>Immunomodulatory Agents and Interventions 1<br \/><strong>Date\/Time:<\/strong> Monday, Apr 17, 2023, 9:00 AM &#8211; 12:30 PM<br \/><strong>Location:\u00a0<\/strong>Section 23<br \/><strong>Poster Board Number:\u00a0<\/strong>19<br \/><strong>Abstract Presentation Number:<\/strong>\u00a01815<\/p>\n<p>Additional meeting information can be found on the AACR website, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WCBJgb2hK2VgeXcB_IJ_JG_Rx5xdy7wfBIixTbbF_FvhckZD_7p6CpE2UH0ddFNvDuzzcgahv6eYKu2TShhQlw==\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/www.aacr.org<\/a>. The poster will be available under <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=dbso6vlGOxQ0GTX-ig3mjkpCIs8gA6GRUnu6yJjlTivqmrFVEcZ-WthDmCS0R5Uywg48CnhxnPTPPqqAVQticcb2QqH7qxDV2NMo4dYL0Lf1xQgsreSPDRrZbAAQ-0XdK58lsFlVuM-eL2IlHzUIIH77iZyJjyZrFmKzfU9LrP3IqjFpwUjLOXfvt6HvBZzyROrQiRgUEbMAM4Rye2FMmY6VFmc2NvI0RIAUs6bgJarKNv4d3Ogku1amEfWTHA1r\" rel=\"nofollow noopener\" target=\"_blank\">Posters<\/a> on the Company\u2019s website shortly after the event<\/p>\n<p>\n        <strong>About Shattuck Labs, Inc.<\/strong><br \/>\n        <br \/>Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck\u2019s proprietary Agonist Redirected Checkpoint, ARC<sup>\u00ae<\/sup>, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules with a single therapeutic. The company\u2019s lead SL-172154 (SIRP\u03b1-Fc-CD40L) program, which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in multiple Phase 1 trials. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN\u2122, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8BH-oPmn7bLBGyDiyk-RxzHtIg5Yso6iSwgFs0nDFG8WdWdG-nVIgWSnJA12yaBAEoI21MSBHvQ_Y8BhKCEQgbVCUXhgd0dlsWp9K3F-UYY=\" rel=\"nofollow noopener\" target=\"_blank\">www.ShattuckLabs.com<\/a>.<\/p>\n<p>The Company intends to use the investor relations portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD.<\/p>\n<p>\n        <strong>Investor &amp; Media Contact: <\/strong><br \/>\n        <br \/>Conor Richardson<br \/>Vice President of Investor Relations<br \/>Shattuck Labs, Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FtJ-G9G-oTbXhoXI9NHpWLZWWlMJrVvsnfCmcHMCnZbH_E5ltoQi4x0i4yUU9F204OqCNvA71hvK--ExbDtfV9BfhXzBPpLNlV26A0PowVr05p8a_6FFUZOTvcib_1uhrcogyMi7mlsMlS7hdAd59g==\" rel=\"nofollow noopener\" target=\"_blank\">InvestorRelations@Shattucklabs.com<\/a>\u00a0<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4OTg3OSM1NDY0NjAyIzIyMDI4MzE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/YTUxYTdiM2EtZjU2My00ZDBjLWE1OWItNDFkMDcxZWFhNDJhLTEyMTQzODQ=\/tiny\/Shattuck-Labs-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>\u2013 CD20-targeted\u00a0GADLEN demonstrated preclinical proof of concept of rapid B cell depletion in humanized mice and non-human primates, intended for clinical development in autoimmune disease \u2013 AUSTIN, TX and DURHAM, NC, March 16, 2023 (GLOBE NEWSWIRE) &#8212; Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease,\u00a0today announced preclinical data at the 2023 American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida, from the company\u2019s GADLEN platform. \u201cWe are pleased to share pre-clinical data demonstrating that the CD20-targeted GADLEN efficiently directs small numbers of human V\u03b39V\u03b42 T cells to serially kill greater than 99% &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shattuck-labs-presents-preclinical-data-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Shattuck Labs Presents Preclinical Data at the 2023 American Association for Cancer Research (AACR) Annual Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-740718","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Shattuck Labs Presents Preclinical Data at the 2023 American Association for Cancer Research (AACR) Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shattuck-labs-presents-preclinical-data-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shattuck Labs Presents Preclinical Data at the 2023 American Association for Cancer Research (AACR) Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"\u2013 CD20-targeted\u00a0GADLEN demonstrated preclinical proof of concept of rapid B cell depletion in humanized mice and non-human primates, intended for clinical development in autoimmune disease \u2013 AUSTIN, TX and DURHAM, NC, March 16, 2023 (GLOBE NEWSWIRE) &#8212; Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease,\u00a0today announced preclinical data at the 2023 American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida, from the company\u2019s GADLEN platform. \u201cWe are pleased to share pre-clinical data demonstrating that the CD20-targeted GADLEN efficiently directs small numbers of human V\u03b39V\u03b42 T cells to serially kill greater than 99% &hellip; Continue reading &quot;Shattuck Labs Presents Preclinical Data at the 2023 American Association for Cancer Research (AACR) Annual Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/shattuck-labs-presents-preclinical-data-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-16T12:36:32+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4OTg3OSM1NDY0NjAyIzIyMDI4MzE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shattuck-labs-presents-preclinical-data-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shattuck-labs-presents-preclinical-data-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Shattuck Labs Presents Preclinical Data at the 2023 American Association for Cancer Research (AACR) Annual Meeting\",\"datePublished\":\"2023-03-16T12:36:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shattuck-labs-presents-preclinical-data-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting\\\/\"},\"wordCount\":628,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shattuck-labs-presents-preclinical-data-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc4OTg3OSM1NDY0NjAyIzIyMDI4MzE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shattuck-labs-presents-preclinical-data-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shattuck-labs-presents-preclinical-data-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting\\\/\",\"name\":\"Shattuck Labs Presents Preclinical Data at the 2023 American Association for Cancer Research (AACR) Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shattuck-labs-presents-preclinical-data-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shattuck-labs-presents-preclinical-data-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc4OTg3OSM1NDY0NjAyIzIyMDI4MzE=\",\"datePublished\":\"2023-03-16T12:36:32+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shattuck-labs-presents-preclinical-data-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shattuck-labs-presents-preclinical-data-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shattuck-labs-presents-preclinical-data-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc4OTg3OSM1NDY0NjAyIzIyMDI4MzE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc4OTg3OSM1NDY0NjAyIzIyMDI4MzE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shattuck-labs-presents-preclinical-data-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shattuck Labs Presents Preclinical Data at the 2023 American Association for Cancer Research (AACR) Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Shattuck Labs Presents Preclinical Data at the 2023 American Association for Cancer Research (AACR) Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/shattuck-labs-presents-preclinical-data-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Shattuck Labs Presents Preclinical Data at the 2023 American Association for Cancer Research (AACR) Annual Meeting - Market Newsdesk","og_description":"\u2013 CD20-targeted\u00a0GADLEN demonstrated preclinical proof of concept of rapid B cell depletion in humanized mice and non-human primates, intended for clinical development in autoimmune disease \u2013 AUSTIN, TX and DURHAM, NC, March 16, 2023 (GLOBE NEWSWIRE) &#8212; Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease,\u00a0today announced preclinical data at the 2023 American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida, from the company\u2019s GADLEN platform. \u201cWe are pleased to share pre-clinical data demonstrating that the CD20-targeted GADLEN efficiently directs small numbers of human V\u03b39V\u03b42 T cells to serially kill greater than 99% &hellip; Continue reading \"Shattuck Labs Presents Preclinical Data at the 2023 American Association for Cancer Research (AACR) Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/shattuck-labs-presents-preclinical-data-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2023-03-16T12:36:32+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4OTg3OSM1NDY0NjAyIzIyMDI4MzE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shattuck-labs-presents-preclinical-data-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shattuck-labs-presents-preclinical-data-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Shattuck Labs Presents Preclinical Data at the 2023 American Association for Cancer Research (AACR) Annual Meeting","datePublished":"2023-03-16T12:36:32+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shattuck-labs-presents-preclinical-data-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting\/"},"wordCount":628,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shattuck-labs-presents-preclinical-data-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4OTg3OSM1NDY0NjAyIzIyMDI4MzE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shattuck-labs-presents-preclinical-data-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/shattuck-labs-presents-preclinical-data-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting\/","name":"Shattuck Labs Presents Preclinical Data at the 2023 American Association for Cancer Research (AACR) Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shattuck-labs-presents-preclinical-data-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shattuck-labs-presents-preclinical-data-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4OTg3OSM1NDY0NjAyIzIyMDI4MzE=","datePublished":"2023-03-16T12:36:32+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shattuck-labs-presents-preclinical-data-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/shattuck-labs-presents-preclinical-data-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shattuck-labs-presents-preclinical-data-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4OTg3OSM1NDY0NjAyIzIyMDI4MzE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4OTg3OSM1NDY0NjAyIzIyMDI4MzE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shattuck-labs-presents-preclinical-data-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Shattuck Labs Presents Preclinical Data at the 2023 American Association for Cancer Research (AACR) Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/740718","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=740718"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/740718\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=740718"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=740718"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=740718"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}